Figure 1.
Basis of ADEPT strategies. The antibody-enzyme conjugate specifically binds to a tumor-specific marker on tumor cells (yellow) and not on normal cells
(green). Upon subsequent systemic application of the prodrug, this is converted to active cytotoxic agent at the site of antibody
binding. The cytotoxic agent exerts is biological effect within the vicinity of antibody binding.